CN1369263A - Flexible vitaminc A acid liposome and its product - Google Patents
Flexible vitaminc A acid liposome and its product Download PDFInfo
- Publication number
- CN1369263A CN1369263A CN 02104247 CN02104247A CN1369263A CN 1369263 A CN1369263 A CN 1369263A CN 02104247 CN02104247 CN 02104247 CN 02104247 A CN02104247 A CN 02104247A CN 1369263 A CN1369263 A CN 1369263A
- Authority
- CN
- China
- Prior art keywords
- retinoic acid
- preparation
- flexible lipidosome
- acid flexible
- lipidosome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002502 liposome Substances 0.000 title claims abstract description 11
- 239000002253 acid Substances 0.000 title abstract 4
- 239000000243 solution Substances 0.000 claims abstract description 7
- 239000002904 solvent Substances 0.000 claims abstract description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims abstract description 4
- 239000006071 cream Substances 0.000 claims abstract description 4
- 229940067606 lecithin Drugs 0.000 claims abstract description 4
- 239000000787 lecithin Substances 0.000 claims abstract description 4
- 235000010445 lecithin Nutrition 0.000 claims abstract description 4
- 239000002674 ointment Substances 0.000 claims abstract description 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims description 43
- 229930002330 retinoic acid Natural products 0.000 claims description 43
- 229960001727 tretinoin Drugs 0.000 claims description 43
- 238000002360 preparation method Methods 0.000 claims description 24
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 229930003427 Vitamin E Natural products 0.000 claims description 7
- 150000001875 compounds Chemical class 0.000 claims description 7
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 235000019165 vitamin E Nutrition 0.000 claims description 7
- 229940046009 vitamin E Drugs 0.000 claims description 7
- 239000011709 vitamin E Substances 0.000 claims description 7
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 6
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 claims description 6
- 230000008859 change Effects 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 102000015731 Peptide Hormones Human genes 0.000 claims description 3
- 108010038988 Peptide Hormones Proteins 0.000 claims description 3
- 230000003115 biocidal effect Effects 0.000 claims description 3
- 229940099352 cholate Drugs 0.000 claims description 3
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 3
- 239000003245 coal Substances 0.000 claims description 3
- 239000000084 colloidal system Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000012467 final product Substances 0.000 claims description 3
- 239000005457 ice water Substances 0.000 claims description 3
- 239000012982 microporous membrane Substances 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 229960002668 sodium chloride Drugs 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 229960005486 vaccine Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 3
- 239000003643 water by type Substances 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 10
- 239000003814 drug Substances 0.000 abstract description 8
- 230000009471 action Effects 0.000 abstract description 2
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 abstract 3
- 239000003833 bile salt Substances 0.000 abstract 1
- 239000007800 oxidant agent Substances 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 6
- 229940079593 drug Drugs 0.000 description 4
- 208000020154 Acnes Diseases 0.000 description 3
- 206010000496 acne Diseases 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000004005 microsphere Substances 0.000 description 3
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- AXTGDCSMTYGJND-UHFFFAOYSA-N 1-dodecylazepan-2-one Chemical compound CCCCCCCCCCCCN1CCCCCC1=O AXTGDCSMTYGJND-UHFFFAOYSA-N 0.000 description 1
- 206010011732 Cyst Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020880 Hypertrophy Diseases 0.000 description 1
- 208000037656 Respiratory Sounds Diseases 0.000 description 1
- 206010040844 Skin exfoliation Diseases 0.000 description 1
- 208000007712 Tinea Versicolor Diseases 0.000 description 1
- 206010048222 Xerosis Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 230000035618 desquamation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014617 hemorrhoid Diseases 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 201000011486 lichen planus Diseases 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 206010035116 pityriasis rubra pilaris Diseases 0.000 description 1
- 208000009954 pyoderma gangrenosum Diseases 0.000 description 1
- 230000009711 regulatory function Effects 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical compound [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
Abstract
A flexible vitamine A acid liposome for treating dermatopathy is disclosed, which contains lecithin, bile salt, vitamine A acid and solvent. Its medicine in the form of solution, cream, or ointment contains said flexible vitamine A acid liposome, anti-oxidizing agent, and solvent. Its advantages are high stability, durable action, high curative effect, and less or no by-effect.
Description
Technical field
The invention belongs to the treating skin disease medicine, particularly utilize flexible lipidosome good transdermal performance, improve a kind of retinoic acid flexible lipidosome and the preparation thereof of retinoic acid treating skin disease effects such as acnes.
Background technology
Retinoic acid has multiple therapeutical effect.Oral to treatment psoriasis (psoriasis), serious nodositas and obstinate cyst hemorrhoid, granulocyte hypertrophy and leukemia, precancerous lesion, as the mucosa day shift of chamber or cervix uteri, and lichen planus, pityriasis rubra pilaris, folliculitis and Pyoderma gangrenosum etc. have obvious therapeutic action; The preparation external of variable concentrations has obvious effects to various acnes, the reparation of corium damage, the removal of skin crackle, exogenous skin aging.In being usually used in,, can produce big side effect, as pimple, erythema, decortication and allergy, xerosis cutis if concentration is big slightly to various remedy of acne; When concentration is low, does not then have keratinization and change.Though multiple retinoic acid preparation is arranged clinically, but because of it fails to solve preferably a transdermal difficult problem, limited in clinical extensive use, the azone that has added concentration and be 0.5%-2% in Chinese patent 97120956.1 " compositions that contains retinoic acid and clindamycin that is used for the treatment of acne " is as the epidermis penetrating agent, improved the transdermal performance, obviously improve therapeutic effect, but have the part patient to still have erythema, the side effect of desquamation produces.The molecule of retinoic acid contains more ethylenic unsaturation chain in addition, and is easily oxidized, therefore will add proper quantity of antioxidant in the carrier of preparation, could keep drug effect.
Summary of the invention
The purpose of this invention is to provide a kind of retinoic acid flexible lipidosome and preparation thereof, comprise retinoic acid flexible lipidosome and compound method and pharmaceutical formulation, it is characterized in that: described retinoic acid flexible lipidosome comprises the double solvents 20-40ml of lecithin 0.001-0.08 gram, cholate 0.001-0.1 gram, retinoic acid 0.01-0.1 gram, chloroform and the preparation of ethanol equivalent; Its compound method is a rotary evaporation in 37 ℃ of water-baths of constant temperature, remove organic molten coal, add 0.9% an amount of sodium-chloride water solution then, rotation was washed film 2 hours, obtain liposome suspension, in temperature be-the ice-water bath condition of 4-20 ℃ under with probe-type supersonic vibration appropriate time, obtain finished product behind the filtering with microporous membrane with 0.1-0.3 μ m at last.
Described retinoic acid flexible lipidosome pharmaceutical formulation and compound method, its prescription comprises by weight percentage: the Ka Baimu 940 of 0.2-0.7%, the vitamin E of 0.1-5%, with the 0.005-0.5% retinoic acid flexible lipidosome that retinoic acid calculates, an amount of triethanolamine and surplus are pure water; Its preparation process is earlier Ka Baimu 940 waters to be soaked a night in right amount, and transferring pH value with triethanolamine is 5.5-7.0, adds vitamin E, retinoic acid liposome and pure water to capacity, after stirring, crosses colloid mill and gets final product.
Described preparation also can be mixed with solution, cream and unguentum, and its formula components, proportioning also change thereupon.
Described flexible lipidosome also can be applicable to antibiotic, hormone, polypeptide, vaccine and vitamin.
The beneficial effect that the present invention reaches is: the retinoic acid flexible lipidosome of the present invention's preparation is a complex; have splendid pliability and automatic regulatory function; on the proliposome basis, added and had surfactant component such as the sodium cholate that makes the film deformation effect; therefore; the flexible lipidosome microsphere can see through the micropore barrier effectively; the aperture of passage also can be passed through less than the average diameter of microsphere even; when flexible lipidosome is applied topically to skin; and it is progressively dry; microsphere is changed gradient downstream and is passed skin; enter health, and do not damage the defencive function of organ.Therefore, macromolecular drug is had transdermal effect preferably, obviously increase the transit dose of small-molecule drug, the retinoic acid after its liposome has: A, and curative effect of medication increases, and stability increases, and oxidation resistance strengthens.Because skin is one of best biological barrier, surface horny layer only is 1/10th of a skin thickness, but undertaking 80% barrier task, the macromole of common drug is blocked by horny layer, the small-molecule substance that enters skin is eliminated fast by blood circulation, accumulation in skin is difficult to, the characteristic that has film deformation because of flexible lipidosome, transdermal is functional, in skin layer, can produce a large amount of, unified, the passage of broad accounts for 80% of skin, so the retinoic acid flexible lipidosome can increase the concentration that medicine sees through skin surface greatly, prolong the action time of retinoic acid under skin, help the performance of drug effect.B reduces the generation of side effect, retinoic acid by liposome after, directly do not contact top layer skin, thereby reduced the side effect generation.
Embodiment
The present invention is retinoic acid flexible lipidosome and preparation thereof.It has therapeutical effect to multiple disease according to retinoic acid, modal is the various types of acnes of treatment, directly contact epidermal area according to the described retinoic acid of background technology and easily produce serious adverse, with contain more ethylenic unsaturation chain in the molecule, easily oxidation, make drug failure, therefore the present invention has prepared retinoic acid flexible lipidosome and preparation thereof, comprise lecithin 0.03631 gram, cholate 0.0603 gram, retinoic acid 0.0332 gram in its retinoic acid flexible lipidosome optimum formula, the double solvents 35ml of chloroform and the preparation of ethanol equivalent; Its compound method is a rotary evaporation in 37 ℃ of water-baths of constant temperature, remove organic molten coal, add 0.9% an amount of sodium-chloride water solution then, rotation was washed film 2 hours, obtain liposome suspension, under-4-25 ℃ ice-water bath condition with probe-type supersonic vibration appropriate time, at last with behind the filtering with microporous membrane of 0.1-0.3 μ m finished product.Use above-mentioned retinoic acid flexible lipidosome to add other compositions and be mixed with retinoic acid flexible lipidosome preparation, its preferred plan comprises by weight percentage: 0.5% Ka Baimu 940,2% vitamin E, with the 0.025% retinoic acid flexible lipidosome that retinoic acid calculates, an amount of triethanolamine and surplus are pure water; Its preparation process is earlier Ka Baimu 940 waters suitably to be soaked a night, and transferring pH value with triethanolamine is 5.5-7.0, adds vitamin E, retinoic acid liposome and pure water to capacity, after stirring, crosses colloid mill and gets final product.The vitamin E of its adding increases the anti-oxidation function of retinoic acid, increases medicine stability and auxiliary treatment dual function.Preparation can be mixed with solution, cream and unguentum, and its formula components, proportioning also change thereupon.
Flexible lipidosome of the present invention can also produce multiple therapeutic effect with multiple components compatibility, promptly can be applicable to antibiotic, vitamin, hormone, polypeptide, vaccine.Use variable concentrations and reach different therapeutic purposes.
Claims (4)
1. retinoic acid flexible lipidosome and preparation thereof, comprise retinoic acid flexible lipidosome and compound method and pharmaceutical formulation, it is characterized in that: described retinoic acid flexible lipidosome comprises the double solvents 20-40ml of lecithin 0.001-0.08 gram, cholate 0.001-0.1 gram, retinoic acid 0.01-0.1 gram, chloroform and the preparation of ethanol equivalent; Its compound method is a rotary evaporation in 37 ℃ of water-baths of constant temperature, remove organic molten coal, add 0.9% an amount of sodium-chloride water solution then, rotation was washed film 2 hours, obtain liposome suspension, in temperature be-the ice-water bath condition of 4-20 ℃ under with probe-type supersonic vibration appropriate time, obtain finished product behind the filtering with microporous membrane with 0.1-0.3 μ m at last.
2. preparation with the preparation of the described retinoic acid flexible lipidosome of claim 1, it is characterized in that: described retinoic acid flexible lipidosome pharmaceutical formulation and compound method are, its prescription comprises by weight percentage: the Ka Baimu 940 of 0.2-0.7%, the vitamin E of 0.1-5%, with the 0.005-0.5% retinoic acid flexible lipidosome that retinoic acid calculates, an amount of triethanolamine and surplus are pure water; Its preparation process is earlier Ka Baimu 940 waters to be soaked a night in right amount, and transferring pH value with triethanolamine is 5.5-7.0, adds vitamin E, retinoic acid liposome and pure water to capacity, after stirring, crosses colloid mill and gets final product.
3. retinoic acid flexible lipidosome and preparation thereof according to claim 1, it is characterized in that: described preparation also can be mixed with solution, cream and unguentum, and its formula components, proportioning also change thereupon.
4. retinoic acid flexible lipidosome and preparation thereof according to claim 1, it is characterized in that: described flexible lipidosome also can be applicable to antibiotic, hormone, polypeptide, vaccine and vitamin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02104247 CN1369263A (en) | 2002-02-26 | 2002-02-26 | Flexible vitaminc A acid liposome and its product |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 02104247 CN1369263A (en) | 2002-02-26 | 2002-02-26 | Flexible vitaminc A acid liposome and its product |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1369263A true CN1369263A (en) | 2002-09-18 |
Family
ID=4740049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 02104247 Pending CN1369263A (en) | 2002-02-26 | 2002-02-26 | Flexible vitaminc A acid liposome and its product |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1369263A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100441187C (en) * | 2006-08-30 | 2008-12-10 | 中国人民解放军第三军医大学第一附属医院 | A liposomal retinoic acid aerosol for treating chronic obstructive pulmonary disease |
| CN101843584A (en) * | 2010-06-02 | 2010-09-29 | 北京大学 | Composite of all-trans-retinoic acid and liposome and application thereof |
| CN101982177A (en) * | 2010-11-09 | 2011-03-02 | 程艳香 | Flexible nano realgar liposome as well as preparation method and application thereof |
| WO2012146110A1 (en) * | 2011-04-27 | 2012-11-01 | Wang Yiming | Insulin-delivering transdermal formulation and preparation method therefor |
| CN103720657A (en) * | 2013-11-19 | 2014-04-16 | 广东丸美生物技术股份有限公司 | Preparation method of deformable liposome and deformable liposome prepared with method |
-
2002
- 2002-02-26 CN CN 02104247 patent/CN1369263A/en active Pending
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100441187C (en) * | 2006-08-30 | 2008-12-10 | 中国人民解放军第三军医大学第一附属医院 | A liposomal retinoic acid aerosol for treating chronic obstructive pulmonary disease |
| CN101843584A (en) * | 2010-06-02 | 2010-09-29 | 北京大学 | Composite of all-trans-retinoic acid and liposome and application thereof |
| CN101843584B (en) * | 2010-06-02 | 2012-05-30 | 北京大学 | A kind of complex of all-trans retinoic acid and liposome and its application |
| CN101982177A (en) * | 2010-11-09 | 2011-03-02 | 程艳香 | Flexible nano realgar liposome as well as preparation method and application thereof |
| WO2012146110A1 (en) * | 2011-04-27 | 2012-11-01 | Wang Yiming | Insulin-delivering transdermal formulation and preparation method therefor |
| CN103720657A (en) * | 2013-11-19 | 2014-04-16 | 广东丸美生物技术股份有限公司 | Preparation method of deformable liposome and deformable liposome prepared with method |
| CN103720657B (en) * | 2013-11-19 | 2017-01-04 | 广东丸美生物技术股份有限公司 | The preparation method of a kind of deformable liposome, and the transmutability liposome of preparation |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0918458B1 (en) | Antimicrobial treatment for herpes simplex virus and other infectious diseases | |
| US6365623B1 (en) | Treatment of acne using lipoic acid | |
| AU2006250763A1 (en) | Epidermal growth factor composition, a process therefor and its application | |
| KR20050089740A (en) | Topical formulation for treatment of rosacea | |
| CN1899272A (en) | Stabilized compositions of aqueous reduced coenzyme q solution | |
| WO2013151341A1 (en) | Injectable composition comprising phosphatidylcholine and method for preparing thereof | |
| US7737130B2 (en) | Pharmaceutical compositions for topical use in treatment of skin or mucous injuries | |
| CN101518522A (en) | Allicin external preparation and prepration method thereof | |
| WO1997039746A1 (en) | Method of and composition for treating disorders of the skin using vitamin k | |
| WO2012076352A1 (en) | Composition for topical use for treating skin disorders | |
| CN1369263A (en) | Flexible vitaminc A acid liposome and its product | |
| JPH07309820A (en) | Medicine composition for dermatotherapy containing o-ester of l-carnitine with aromatic acid | |
| CN101485675A (en) | Adapalene and hydrochloric clindamycin compound gel preparation and preparation method thereof | |
| US7060729B2 (en) | Composition and method for treating skin | |
| CN108653304A (en) | A kind of pterostilbene nano-micelle external-use gel and preparation method thereof | |
| US20110123600A1 (en) | Use of alkylureas for treating acne | |
| US20150306221A1 (en) | Mixture of Betamethasone and Tranilast with a Transdermal Gel for Scar Treatment | |
| ES2275889T3 (en) | USE OF ANTIDIABETIC AGENTS TO MANUFACTURE A MEDICINAL PRODUCT THAT HAS A CICATRIZING EFFECT. | |
| CN112516151B (en) | Cholecalciferol sulfate salts and their use for the treatment of vitamin D3Use of deficiency | |
| Mishra et al. | Topical antibiotics and semisolid dosage forms | |
| US5696099A (en) | Topical preparations for the treatment of acne and acneiform dermatitis | |
| JPH04500684A (en) | External skin preparation of water-soluble vitamin A for application to the skin | |
| CN104027346B (en) | Medicament composition for treating wound fester and preparation method thereof | |
| CN1478485A (en) | Liposome ointment containing heparin drugs and preparation method thereof | |
| CN115006521B (en) | Acne-removing gel containing lysozyme |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |